AZD 8955
Alternative Names: AZD8955Latest Information Update: 21 Mar 2007
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Collagenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 01 Feb 2007 Discontinued - Phase-II for Osteoarthritis (unspecified route)
- 08 Jun 2006 Phase-II clinical trials in Osteoarthritis (unspecified route)
- 04 Aug 2004 Phase-I clinical trials in Osteoarthritis (unspecified route)